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Aims Cardiac arrhythmias comprise a major health and economic burden and are associated with significant morbidity
and mortality, including cardiac failure, stroke, and sudden cardiac death (SCD). Development of efficient preven-
tive and therapeutic strategies is hampered by incomplete knowledge of disease mechanisms and pathways. Our




We employed a phenotype-driven N-ethyl-N-nitrosourea mutagenesis screen and identified a mouse line with
a high incidence of sudden death at young age (6–9 weeks) in the absence of prior symptoms. Affected mice
were found to be homozygous for the nonsense mutation Bcat2p.Q300*/p.Q300* in the Bcat2 gene encoding
branched chain amino acid transaminase 2. At the age of 4–5 weeks, Bcat2p.Q300*/p.Q300* mice displayed drastic
increase of plasma levels of branch chain amino acids (BCAAs—leucine, isoleucine, valine) due to the
incomplete catabolism of BCAAs, in addition to inducible arrhythmias ex vivo as well as cardiac conduction and
repolarization disturbances. In line with these findings, plasma BCAA levels were positively correlated to
electrocardiogram indices of conduction and repolarization in the German community-based KORA F4 Study.
Isolated cardiomyocytes from Bcat2p.Q300*/p.Q300* mice revealed action potential (AP) prolongation,
pro-arrhythmic events (early and late afterdepolarizations, triggered APs), and dysregulated calcium
homeostasis. Incubation of human pluripotent stem cell-derived cardiomyocytes with elevated concentration
of BCAAs induced similar calcium dysregulation and pro-arrhythmic events which were prevented by
rapamycin, demonstrating the crucial involvement of mTOR pathway activation.
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Conclusions Our findings identify for the first time a causative link between elevated BCAAs and arrhythmia, which has
implications for arrhythmogenesis in conditions associated with BCAA metabolism dysregulation such as diabetes,
metabolic syndrome, and heart failure.
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1. Introduction
Cardiac arrhythmias comprise a major health and economic burden
and are associated with significant morbidity and mortality, including
cardiac failure, stroke, and sudden cardiac death (SCD). SCD
remains a leading cause of mortality in the Western world, account-
ing for up to 20% of all natural deaths, and up to 50% of all cardiovas-
cular deaths.1 Arrhythmias typically occur in the setting of an
underlying pathology, including myocardial ischaemia, structural
derangements, and co-morbidities such as hypertension.1,2
Furthermore, patients suffering from metabolic disorders (diabetes,
obesity) and heart failure are at increased risk for arrhythmias and
SCD.3–8 Despite decades of research, few anti-arrhythmic thera-
peutic options exist due to the complexity of underlying patholo-
gies. Development of efficient preventive and therapeutic strategies
is essential but is as yet hampered by incomplete knowledge of dis-
ease mechanisms.
Over the last decade, we and others have employed several novel
approaches to identify new disease mechanisms and pathways regu-
lating cardiac electrical (dys)function, including genomic studies in
rodents.9,10 Phenotype driven screens have been very successful in
identifying novel genes and alleles associated with disease, and
resolving gene function.11,12 In N-ethyl-N-nitrosourea (ENU) muta-
genesis screens, pedigrees of mice with randomly induced point
mutations are screened for a range of phenotypes and affected mice
are subsequently used to map and clone the causative allele.13
Employing such a phenotype-driven ENU screen, we here identified
a mutant mouse line presenting with sudden death and a homozy-
gous nonsense mutation in the Bcat2 gene. Affected mice displayed
a drastic increase of plasma branched chain amino acid (BCAA—va-
line, isoleucine, leucine) levels due to the incomplete catabolism of
BCAAs, enhanced arrhythmia susceptibility, cardiac conduction and
repolarization disturbances, and excessive pro-arrhythmic intracel-
lular calcium dysregulation in isolated cardiomyocytes. In support of
a role for BCAAs in modulation of cardiac electrical function,
plasma BCAA levels were positively correlated to electrocardio-
gram (ECG) indices of conduction and repolarization in individuals
from the general population.14 Studies in human pluripotent stem
cell-derived cardiomyocytes (hPSC-CMs) furthermore confirmed a
direct pro-arrhythmic effect of elevated BCAAs and demonstrated
the crucial involvement of the mammalian target of rapamycin
(mTOR) activation in mediating these effects. Our findings thus
demonstrate a causative link between elevated BCAAs and arrhyth-
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mechanisms underlying lethal arrhythmias, particularly those occur-
ring in disease states associated with elevated BCAA levels such as
diabetes and metabolic syndrome.4–6,14–17
2. Materials and methods
2.1 Mice
All animals were housed and maintained in the Mary Lyon Centre at
MRC Harwell, under specific pathogen-free conditions in individually
ventilated cages, with environmental conditions as outlined in the Home
Office Code of Practice. Home Office ethical approval was granted un-
der project license 30/3070 and mice were euthanized by Home Office
Schedule 1 methods. All experiments involving mice conformed to gov-
ernmental and institutional guidelines for animal use in research and
were performed with approval of the Animal Experimental Committee
of the Academic Medical Center, Amsterdam (license
AVD1180020184986). For ECG measurements, general anaesthesia was
induced with 4.0% isoflurane and maintained at 0.8–1.2% isoflurane in
oxygen. Euthanasia was performed by 100% CO2 administration (20% v/
v per minute), followed by cervical dislocation.
2.2 Generation of mutagenized pedigrees
The details of the ENU program have been described previously.11
Briefly, C57BL/6J male mice (G0) were treated with ENU doses of 1 
120 mg kg–1, and then 2 100 mg kg–1with a week between each dose.
The mice were then bred with wild-type ‘sighted C3H’ (C3H.Pde6bþ)
females.12 The resulting G1 males were bred with wild-type
C3H.Pde6bþ females to produce G2 females, which were backcrossed
to their G1 fathers to generate G3 offspring. The G3 mating scheme
results on average in 1 in 8 G3 mice homozygous for any particular ENU-
induced mutation. Binomial probability calculations indicate that a cohort
of 50 single sex mice will yield 4 homozygotes with a probability of
85% and 5 with a probability of 75%. Initial identification of the sud-
den death phenotype was in G3 mice (batch A) but subsequent studies
employed mice backcrossed ten generations to the C3H.Pde6bþ back-
ground (batch B). Measurements and experiments were performed in
mice of either sex at the age of 4–5 weeks, unless otherwise specified (as
further specified in the Supplementary material online).
2.3 Mapping and DNA sequencing
DNA from affected mice and littermates was prepared from ear biopsies
and used for linkage mapping utilizing the Illumina GoldenGate Mouse
Medium Density Linkage Panel (Gen-Probe Life Sciences Ltd, UK). DNA
from the founder G1 mouse was prepared for whole-genome sequenc-
ing (WGS) using the Nucleon BACC2 Genomic DNA Extraction
System (GE Healthcare Life Sciences). After library generation, a single
lane of paired-end sequencing (100 nt) was performed employing the
Illumina HiSeq platform (Oxford Genomics Centre, Wellcome Trust
Centre for Human Genetics) and analysed as previously described.11
Genetic variants identified by WGS were confirmed by pyrosequencing
(see Supplementary material online).
2.4 NMR methodology and biochemical
screen
Because of the severe nature of the phenotype and risk of early death,
the phenotyping of this line was limited primarily to post mortem analy-
sis. The function of the Bcat2 gene suggested the possibility of abnormal
levels of metabolites such as branched chain amino acids. To prevent the
unnecessary death of mice, urine and plasma of male and female mice
aged between 4 and 5 weeks of age were analysed by NMR. Details on
urine and plasma sample preparation, NMR analysis, and estimation of
the valine and xleucine (leucine and isoleucine combined) concentra-
tions from the NMR spectra are provided in the Supplementary material
online. Further analysis of plasma was carried out by a clinical chemistry
analysis of terminal plasma samples; further details are provided in the
Supplementary material online, Table S1.
2.5 Western blot analysis of WTand
p.Q300* BCAT2 protein expression
Full length cDNA clone of BCAT2 (Dharmacon) was ligated into the
pCMV6-AN-Myc vector (Origene), and the C1121T mutation was intro-
duced by Q5 site-directed mutagenesis. Plasmids were transfected into
HEK293T cells followed by western blot analysis as detailed in the
Supplementary material online.
2.6 mTOR and P-mTOR (Ser2448) protein
expression in mouse hearts
Hearts from Bcat2þ/þ and Bcat2pQ330*/pQ330* homozygous males were
harvested between 5 and 6 weeks of age and snap frozen in liquid nitro-
gen. Proteins were extracted from cardiac apex in RIPA buffer and 40mg
of protein was loaded for each sample. Primary antibodies used were
mTOR 1:1000 (Cell signalling technology, ref: 2972); mTOR-P-ser2448
1:1000 (Cell signalling technology, ref: 2971), GAPDH 1:10 000
(Fitzgerald, ref: 10R-G109A), and goat anti-rabbit and anti-mouse horse-
radish peroxidase–conjugated secondary antibodies from GE
Healthcare Life Science (ref: NA9310V and NA9340V, respectively; 1:10
000). For each blot, total mTOR and mTOR-P-ser2448 protein expres-
sion protein were normalized to the GAPDH signal. Full details are pro-
vided in the Supplementary material online.
2.7 Cardiac structural abnormalities
To assess the presence of cardiac hypertrophy, heart weight/body
weight, and heart weight/tibia length ratios were calculated. Histological
assessment of cardiac tissue was carried out on haematoxylin and eosin
stained tissue obtained from 6-week-old G3 mice. Both female and male
mice were included in the quantification.
2.8 ECG measurements, arrhythmia
inducibility testing, and optical mapping
Surface ECG measurements were performed in mice anaesthetized by
isoflurane inhalation using the Powerlab acquisition system
(ADInstruments). Cardiac arrhythmia inducibility was assessed in iso-
lated, Langendorff-perfused hearts. Atria and ventricles were stimulated
at a basic cycle length (BCL) of 120 ms and arrhythmia inducibility was
evaluated using up to three extrastimuli (S1-S2-S3) and burst pacing.
Optical mapping was carried out in Langendorff-perfused hearts paced
at a BCL of 120 ms from the centre of the ventricular epicardial surface.
Optical action potentials (APs) were analysed, and local activation de-
fined as the maximum positive slope of the AP was calculated using cus-
tom software. Measured local activation times were used to construct
ventricular activation maps and calculate conduction velocity in longitu-
dinal and transversal directions. For all electrophysiological measure-
ments, both female and male mice (aged 4–5 weeks) were used. More
details can be found in the Supplementary material online.






























































































2.9 Human pluripotent stem cell-derived
cardiomyocytes
Cor4.U control hPSC-CMs were purchased from Ncardia (Leiden, The
Netherlands) and were plated on gelatin (0.1% diluted in PBS) coated
coverslips at a density of 5000 cells per coverslip following manufac-
turer’s instructions. The generation and use of these cells were conform
to the declaration of Helsinki. Cells were first plated in complete culture
medium (Ncardia) for 24 h and then cultured for 3–4 days in PMC me-
dium (Ncardia) with modified branched chain amino acid (BCAA) con-
centration. BCAA concentrations in control condition were normalized
to 800 nmol/L and supplemented to similar concentrations as quantified
by NMR in plasma samples from Bcat2p.Q300*/p.Q300* mice (i.e. valine:
10 mmol/L; leucine: 7.5 mmol/L; isoleucine: 4.5 mmol/L). BCAAs were
purchased from Sigma-Aldrich and diluted in PMC medium. Rapamycin
(Sigma-Aldrich) was dissolved in dimethyl sulfoxide (DMSO) at a stock
concentration of 20 mmol/L. For experiments, Rapamycin was used at a
concentration of 500 nmol/L diluted in PMC medium (final DMSO con-
centration 0.0025%).
2.10 Action potential measurements
Details on isolation of ventricular mouse cardiomyocytes and AP meas-
urements are provided in the Supplementary material online. In short,
APs were measured at 36C and were elicited at 2 Hz in mouse cardio-
myocytes and 1 Hz in hPSC-CMs. Typically, hPSC-CMs have a small or
even complete lack of the inward rectifying potassium current (IK1).
Consequently, hPSC-CMs have a depolarized resting membrane poten-
tial (RMP) and are frequently spontaneously active.18 To overcome
these conditions, we injected an in silico IK1 with kinetics of Kir2.1 channel
through dynamic clamp,19 as previously described and validated.20,21
Consequently, cells became quiescent with an RMP of around -82 mV.
We analysed RMP, AP amplitude (APA), maximal AP upstroke velocity
(Vmax), and APD at 20%, 50%, and 90% repolarization (APD20, APD50,
and APD90, respectively). The fast-pacing protocol used to count and
quantify early after depolarizations (EADs), delayed after depolarizations
(DADs), and triggered APs (TAPs) consisted of 20 pulses at a frequency
of 5 Hz followed by a 10 s pause. Average results were obtained from
five consecutive traces.
2.11 Intracellular calcium measurements
Calcium transients were measured at 37C in Tyrode solution (see
Supplementary material online) in isolated myocytes stimulated at 6 Hz
using the fluorescent probe Indo-1 as described previously.22 Calcium
after-transients were elicited in myocytes stimulated at 6 Hz in which
stimulation was stopped and spontaneous activity was recorded for
10 s.23 Rapid cooling, which causes complete depletion of calcium from
the sarcoplasmic reticulum (SR), was used to estimate SR calcium con-
tent as described previously.23 Calcium transient decay time was deter-
mined using a mono-exponential fit.
2.12 Association between plasma BCAA
levels and ECG measures in the KORA F4
Study
The community-based KORA Study (Cooperative Health Research in
the Augsburg Region) was conducted in Augsburg, Southern
Germany.14 The KORA F4 Study recruited 3080 participants between
2006 and 2008. All study participants provided written informed
consent, and the study was approved by the Bayerische
Landesärztekammer and is conform to the declaration of Helsinki.
Peripheral blood from fasting individuals was drawn for biomarker analy-
ses. In all participants, a standard 12-lead ECG was obtained after
10 minutes rest in supine position. All participants underwent metabolic
profiling using the Biocrates AbsoluteIDQp150 kit (Biocates Life
Sciences AG, Innsbruck, Austria). For the current analysis, mmol/L con-
centrations of the BCAAs valine and xleucine (i.e. the combination of
leucine and isoleucine) were used. Further details on data collection and
exclusion criteria are provided in the Supplementary material online.
Overall, 776 participants were excluded, leaving 2304 individuals in the
final data set.
2.13 Statistical analysis
No statistical methods were used to predetermine sample size.
Differences between two unpaired groups were assessed using two-
tailed t-tests when following a normal distribution and Mann-Whitney
Rank sum test if normality test failed. Differences comparing three
groups, when normally distributed were assessed using one-way analysis
of variance (ANOVA) with Student–Newman–Keuls post hoc test and
using one-way ANOVA on ranks (Dunn’s method post hoc) when data
were not normally distributed. All statistical tests were performed using
sigma stat 3.5 software (Systat Software, Inc). Variability in all plots and
graphs is presented as the S.E.M. All P < 0.05 were considered to be sig-
nificant. *P < 0.05; **P <_ 0.01; #P <_ 0.001. Summary statistics are depicted
in Supplementary material online, Tables S2–S9. To determine a relation
between ECG measures and BCAAs in the KORA population, linear re-
gression models were fitted, adjusting for sex. Multiplicative interaction
terms showed no statistical interactions with age or sex, and interaction
terms were removed from the final models. All statistical analyses in
KORA were performed using STATA 12.0 (StataCorp LP, College
Station, TX, USA).
3. Results
3.1 Sudden death phenotype in
homozygous Bcat2p.Q300*/p.Q300* mice
Following ENU mutagenesis of C57BL/6J male mice (G0) and successive
rounds of breeding with C3H.Pde6bþ females (Figure 1A), G3 cohorts of
mutagenized animals were produced for longitudinal phenotyping stud-
ies as part of the Harwell Ageing Screen.11 Mice from a single pedigree,
consisting of mixed background G3 mice died suddenly with no obvious
cause and in the absence of preceding symptoms such as tremoring or
gait abnormalities, between 6 and 9 weeks of age (batch A; Figure 1B).
Mapping was performed on the basis that homozygous ENU-induced
mutations must lay in a region of C57BL/6J homogeneity and a region
was identified on chromosome 7 spanning from 28.8 Mb to 56.1 Mb.
WGS of the G1 founder male revealed two high confidence coding
mutations within the mapped region, Bcat2C1121T and SiglechC751T result-
ing in a Q300* and Q219* nonsense mutation, respectively.
Pyrosequencing confirmed that both mutations were present in individu-
als affected by the sudden death phenotype but absent from unaffected
controls. Further breeding eliminated Siglech as a candidate by narrowing
the mapped region and confirmed that all affected mice suffering sudden
death were homozygous for the nonsense mutation Bcat2C1121T in the
gene encoding branched chain aminotransferase 2 (Supplementary






























































..material online, Figure S1). No heterozygous Bcat2C1121T or wild-type
mice succumbed to sudden death before the age of eight weeks and no
homozygous mice lived beyond this age (batch B; Figure 2A). The
Bcat2C1121T mutation results in an early stop (Q300*) and consequently
a truncated BCAT2 protein lacking the CXXC motif essential for en-
zyme catalytic activity and substrate orientation (Supplementary material
online, Figure S2). Plasma clinical chemistry revealed increased levels of
triglycerides, fatty acids, and glycerol, as well as LDL in homozygous
Bcat2p.Q300*/p.Q300* mice and intermediate levels in heterozygous
Bcat2þ/p.Q300* mice (Supplementary material online, Figure S3 and Table
S3). Homozygous Bcat2p.Q300*/p.Q300* mice exhibited increased potas-
sium but decreased chloride concentration in plasma, and increased iron
levels. Whilst significant, none of these data provide a clear explanation
for the sudden death phenotype.
3.2 Accumulation of branched chain amino
acids in plasma and urine of Bcat2p.Q300*/
p.Q300* mice
BCAT2 is located in the mitochondria of most cells of the body and is re-
sponsible for catabolizing BCAAs (leucine, isoleucine, and valine), essen-
tial amino acids that must be obtained from dietary sources. Following
catabolism to their respective a-keto acids (BCKA), BCAAs are further
catabolized by the branched-chain keto acid dehydrogenase complex
(BCKDC), and the final catabolic products (acetyl-CoA and succinyl-
CoA) are ultimately consumed in mitochondria for respiration through
the tri-carboxylic acid cycle.24 In line with this, NMR analysis of plasma
revealed an up to 10-fold increase in plasma levels of BCAAs (but no in-
crease in BCKAs, which were under the detection threshold) in
Bcat2p.Q300*/p.Q300* mice aged 5 weeks (Figure 2B–D). Similar accumula-
tion of BCAAs was observed in the urine of mutant mice aged 5 weeks
(Supplementary material online, Figure S4). Hence, the identified muta-
tion resulted in a truncated BCAT protein with consequent accumula-
tion of BCAAs but not BCKAs. Heterozygous Bcat2þ/p.Q300* mice did
not display sudden death or any other overt phenotype up to the age of
6–8 months, showed normal BCAA plasma levels (Figure 2B–D), and
hence were not investigated further.
3.3 Bcat2p.Q300*/p.Q300* mice display cardiac
electrical alterations and increased
arrhythmia inducibility
Given the absence of overt prior symptoms in Bcat2p.Q300*/p.Q300* mice,
we hypothesized a cardiac basis for their sudden death. No cardiac struc-
tural changes such as hypertrophy, dilation or fibrosis were observed in
Bcat2p.Q300*/p.Q300* hearts upon histological examination
(Supplementary material online, Figure S5A–C, Table S2). We therefore
performed detailed electrophysiological analysis in mice aged 4–5 weeks,
well before the age of 6 weeks at which they started dying suddenly. Due
to their young age and hence small size, and considering needed recov-
ery time post-surgery, in vivo telemetric Holter monitoring was not pos-
sible. However, surface ECGs under isoflurane anaesthesia revealed
significantly prolonged QT, QTc and PR intervals in Bcat2p.Q300*/p.Q300*
compared to Bcat2þ/þ mice (Figure 3A and B, Supplementary material
online, Table S2). We next investigated the ex vivo cardiac electrophysio-
logical differences between Bcat2þ/þ and Bcat2p.Q300*/p.Q300* isolated,
Langendorff-perfused hearts. Atrioventricular (AV) conduction time was
significantly increased in Bcat2p.Q300*/p.Q300* mice (Figure 3C and D,
Supplementary material online, Table S2), similar to the increased PR-
interval observed on ECG analysis. Optical mapping experiments
revealed no differences in ventricular conduction between the groups
(Supplementary material online, Figure S6A and B, Table S2).
Nevertheless, repolarization time (APD70) was significantly prolonged in
Bcat2p.Q300*/p.Q300* compared to Bcat2þ/þ hearts (60.4± 6.0 ms and
43.9± 3.1, respectively; P < 0.05—Figure 3E and F), in line with the ob-
served QTc-prolongation on the surface ECG. Furthermore, the differ-
ence between the longest and shortest APD70 was also significantly
increased in Bcat2p.Q300*/p.Q300* (16.3± 1.3 ms) as compared to Bcat2þ/þ
hearts (9.1± 1.3 ms; P < 0.05) (Supplementary material online, Table S2),
suggesting increased pro-arrhythmic APD heterogeneity. Arrhythmia in-
ducibility studies in Langendorff-perfused hearts showed an increased in-
cidence of inducible arrhythmias in Bcat2p.Q300*/p.Q300* mice compared
to Bcat2þ/þ (50% vs. 11.1%, respectively), the majority of which were
non-sustained (Figure 3G and H).
Figure 1 ENU mutagenesis-induced sudden death phenotype in young mice. (A) Breeding scheme used to produce G3 phenotyping cohorts. C57BL/
6J males were mutagenized with ENU and crossed to C3H.Pde6bþ females. G1 males were then crossed again to C3H.Pde6bþ females, producing a G2
generation. Finally, G2 females were crossed to the G1 male parent to produce a G3 phenotyping cohort. (B) Mortality curve of the initial G3 phenotyp-
ing pedigrees (batch A; n = 154 mice) demonstrating a clear early death phenotype between 6 and 9 weeks of age.






























..3.4 Action potential prolongation, calcium
dysregulation, and pro-arrhythmic events
in Bcatp.Q300*/p.Q300* cardiomyocytes
We next investigated the cellular electrophysiological alterations under-
lying the observed pro-arrhythmia in Bcat2p.Q300*/p.Q300* mice. Figure 4A
shows typical APs and maximal upstroke velocities (Vmax) elicited at a
pacing frequency of 2 Hz in isolated left ventricular cardiomyocytes iso-
lated from Bcat2þ/þ and Bcat2p.Q300*/p.Q300* hearts. Vmax, APA, and AP
duration at 90% repolarization (APD90) were significantly increased in
Bcat2p.Q300*/p.Q300* compared to Bcat2þ/þ cardiomyocytes (Figure 4B,
Supplementary material online, Table S4). Using a fast pacing (20 pulses
at 5 Hz) protocol, the presence of pro-arrhythmic events was evaluated,
including EADs, DADs and TAPs (indicated by arrows in Figure 4C). The
incidence of TAPs and EADs was significantly higher in Bcat2p.Q300*/
p.Q300* as compared to Bcat2þ/þ cardiomyocytes (Figure 4D). The
observed increase in Vmax, APD90 and EAD incidence was not associated
with alterations in sodium current: although Bcat2p.Q300*/p.Q300* cardio-
myocytes showed a hyperpolarizing shift in both activation and inactiva-
tion, the peak current density, window current, and late sodium current
density were not altered (Supplementary material online, Figure S7 and
Table S4).
Since intracellular calcium dysregulation often underlies pro-
arrhythmic DADs and TAPs, we next explored calcium homeostasis in
isolated cardiomyocytes. Figure 5A shows typical calcium concentration
([Ca2þ]i) transients elicited at a pacing frequency of 6 Hz. On average,
Bcat2p.Q300*/p.Q300* cardiomyocytes showed increased intracellular dia-
stolic calcium levels ([Ca2þ]i), higher [Ca
2þ]i transients, and increased
transient amplitudes as compared to Bcat2þ/þ cells (Figure 5B,
Supplementary material online, Table S5). SR content measured by rapid
cooling was also significantly increased in Bcat2p.Q300*/p.Q300* cardiomyo-
cytes (Supplementary material online, Figure S8A and B), while the ratio
Figure 2 Homozygous Bcat2p.Q300*/p.Q300* mice display sudden death and increased plasma BCAA levels at young age. (A) Mortality curve displaying
death of all homozygous Bcat2p.Q300*/p.Q300* mice (batch B) by the age of 8 weeks. (B) Illustrative water suppressed spin-echo proton NMR spectra of
free-fed plasma from Bcat2þ/þ, Bcat2þ/p.Q300*, and Bcat2p.Q300*/p.Q300* mice at 5 weeks of age. The NMR spectra were plotted such that the aC1 proton
of glucose at 5.23 ppm (not shown) was of similar intensity in each data set. The prominent metabolites shown in the expanded region are assigned to: (1)
lactate, (2) glucose, (3) including b-glucose, (4) choline-containing compounds, (5) acetate, (6) alanine, (7) mobile lipid CH2, (8) 2,3-butanediol, (9) mobile
lipid CH3, (10) branched chain amino acids (BCAAs). (C) NMR spectra from Bcat2
þ/þ, Bcat2þ/p.Q300*, Bcat2p.Q300*/p.Q300* further expanded (zoom do-
main 10) to illustrate the branched chain amino acid -CH3 region with metabolites assigned to (11) valine, (12) isoleucine, (13) leucine. (D) BCAA plas-
matic quantification in Bcat2þ/þ (n = 11), Bcat2þ/p.Q300* (n = 9) and Bcat2p.Q300*/p.Q300* (n = 7) mice. *P < 0.05, one-way ANOVA on ranks with post hoc
Dunn’s method.



















..between diastolic [Ca2þ]i and SR content was not different between
groups (Supplementary material online, Table S5). Moreover, mRNA ex-
pression levels of Slc8a1 [sodium/calcium exchanger (NCX)] and Atp2a2
(SERCA) were unchanged (Supplementary material online, Figure S9 and
Table S2). Figure 5C shows typical examples of calcium after-transients
recorded following a fast-pacing protocol (20 pulses at 6 Hz) using field
stimulation. These calcium after-transients were separated into two
groups based on their amplitude: (i) after-transients of low amplitude
considered not to trigger an AP, and (ii) high-amplitude after-transients
capable of triggering an AP (i.e. TAP). The total number of calcium after-
transients (triggered and non-triggered combined) was significantly
higher in Bcat2p.Q300*/p.Q300* compared to Bcat2þ/þ cardiomyocytes
(Figure 5C and D, Supplementary material online, Table S5), indicating a
calcium-dependent pro-arrhythmia mechanism. The addition of
50 nmol/L noradrenaline significantly increased diastolic [Ca2þ]i, systolic
[Ca2þ]i and transient amplitude in Bcat2
þ/þ cardiomyocytes, but only
Figure 3 Homozygous Bcat2p.Q300*/p.Q300* mice display ECG abnormalities in vivo and atrio-ventricular delay, prolonged repolarization and arrhythmia
inducibility ex vivo. (A) Typical ECG traces obtained under isoflurane anaesthesia for Bcat2þ/þ and Bcat2p.Q300*/p.Q300* mice. (B) Average values for heart
rate, QRS interval, PR interval, QT and QTc (corrected) for both Bcat2þ/þ (n = 11) and Bcat2p.Q300*/p.Q300* (n = 15) mice aged 4–5 weeks. (C) Typical
examples of atrio-ventricular (AV) delay measurements in Langendorff-perfused isolated hearts (right atrial stimulation at a basic cycle length of 120 ms).
(D) Average values for AV-delay in Bcat2þ/þ and Bcat2p.Q300*/p.Q300* hearts. (E) Typical left ventricular repolarization maps obtained from optical mapping
experiments on perfused explanted hearts during central stimulation (6.6 Hz). (F) Average APD70 (action potential duration at 70% of repolarization) val-
ues for Bcat2þ/þ (n = 7) and Bcat2p.Q300*/p.Q300* (n = 7) mice. *P < 0.05, Student’s t-test. (G) Typical example of a short run of ventricular tachycardia in-
duced in an isolated, Langendorff-perfused Bcat2p.Q300*/p.Q300* heart following a short-coupled paced beat. (H) Bar graph representing the percentage of
arrhythmic events recorded on Bcat2þ/þ and Bcatp.Q300*/p.Q300* mouse explanted hearts. *P < 0.05, Student’s t-test.































..marginally in Bcat2p.Q300*/p.Q300* cardiomyocytes (Supplementary mate-
rial online, Table S5). Nevertheless, noradrenaline significantly increased
the number of calcium after-transients in both Bcat2þ/þ and
Bcat2p.Q300*/p.Q300* cardiomyocytes (Supplementary material online,
Table S5).
3.5 Direct pro-arrhythmic effects of BCAAs
in human PSC-derived cardiomyocytes
To demonstrate a direct causal link between elevated BCAAs and pro-
arrhythmia, we evaluated the cellular electrophysiological consequences
of increased BCAA levels in cultured hPSC-CMs. Incubation of hPSC-
CMs for 5 days with BCAA levels similar to those observed in plasma of
Bcat2p.Q300*/p.Q300* mice resulted in significant prolongation of APD90
(Figure 6A and B, Supplementary material online, Table S6), and signifi-
cantly increased the occurrence of pro-arrhythmic early and delayed
afterdepolarizations (EAD/DAD) as compared to hPSC-CMs cultured in
control medium (Figure 6C and D, Supplementary material online, Table
S6), hence recapitulating the findings observed in Bcat2p.Q300*/p.Q300* car-
diomyocytes. Incubation of valine alone induced similar APD90 prolonga-
tion and increased EAD/DAD incidence, while alanine (as a general
amino acid control) had no effects (Supplementary material online,
Figure S10A–D, Table S8). Similar to Bcat2p.Q300*/p.300* cardiomyocytes,
hPSC-CMs cultured in medium with increased BCAA concentration also
displayed intracellular calcium dysregulation, including increased diastolic
[Ca2þ]i and after-transients (Figure 7A–D, Supplementary material online,
Table S6), further confirming a direct pro-arrhythmic effect.
3.6 Pro-arrhythmic effects of elevated
BCAA levels are mediated by mTOR path-
way activation
In addition to their role in energy balance, BCAAs function as potent
nutrient signal molecules to promote protein synthesis, cellular
Figure 4 Abnormal repolarization and pro-arrhythmic events in Bcatp.Q300*/p.Q300* isolated cardiomyocytes. (A) Typical examples of action potentials
(AP) and upstroke velocities (dV/dtmax; inset) elicited at a stimulation frequency of 2 Hz in left ventricular (LV) isolated cardiomyocytes from Bcat2
þ/þ
and Bcat2p.Q300*/p.Q300* mice aged 4–5 weeks. (B) Average values for APA (action potential amplitude), RMP (resting membrane potential), Vmax (upstroke
velocity), and APD (action potential duration) at 20%, 50%, and 90% repolarization (APD20, APD50, and APD90) of LV cardiomyocytes isolated from
Bcat2þ/þ (n = 15 cells from 6 independent cardiomyocyte dissociations) and Bcat2p.Q300*/p.Q300* (n = 9 cells from 5 independent cardiomyocyte dissocia-
tions) mice. (C) Typical examples of early afterdepolarizations (EADs: 1), delayed afterdepolarizations (DADs: 2), and triggered action potentials (TAPs:
3) recorded after a fast pacing stimulation protocol (20 pulses at 5 Hz followed by a 9 s pause and 1 pulse followed by a 500 ms pause) in Bcat2þ/þ and
Bcat2p.Q300*/p.Q300* LV cardiomyocytes. (D) Average count per trace for DADs, TAPs and EADs observed in Bcat2þ/þ (n = 10 cardiomyocytes from 6
mice) and Bcat2p.Q300*/p.Q300* mice (n = 5 cardiomyocytes from 4 mice). Average numbers were calculated using five consecutive traces. (with Student’s
t-test or Mann–Whitney Rank sum test).













..metabolism, and cell growth in a mammalian target of rapamycin
(mTOR)-dependent manner,24,25 and elevated BCAA concentrations
have been shown to lead to chronic induction of mTOR activity and
increased oxidative stress.26,27 Indeed, cardiac tissue from Bcat2p.Q300*/
p.Q300* mice showed significantly higher expression levels of both mTOR
total protein and activated P-mTOR as compared to Bcat2þ/þ
(normalized for GAPDH), in addition to an increased P-mTOR to
mTOR ratio, indicating mTOR pathway activation (Figure 5E and F,
Supplementary material online, Table S2). In line with mTOR pathway ac-
tivation, the mRNA expression level of the pro-hypertrophic marker Anf
Figure 5 Abnormal intracellular calcium and myocardial mTOR upregulation in Bcat2p.Q300*/p.Q300* mice. (A) Typical intracellular calcium transient re-
cording performed at a pacing frequency of 6 Hz and (B) average values for diastolic Ca2þ, peak transient and transient amplitude of LV cardiomyocytes
from Bcat2þ/þ (n = 12 cardiomyocytes from 5 independent cardiomyocyte dissociations) and Bcat2p.Q300*/p.Q300* (n = 17 cardiomyocytes from 4 inde-
pendent cardiomyocyte dissociations) mice aged 4-5 weeks. (C) Typical example of calcium after-transients in isolated cardiomyocytes from Bcat2þ/þ
and Bcat2p.Q300*/p.Q300* cardiomyocytes following a fast pacing protocol using field stimulation and (D) quantification of non-triggered action potential
(AP) Ca2þ transient, triggered AP Ca2þ transient and total Ca2þ transient events in Bcat2þ/þ (n = 9 cardiomyocytes from 3 mice) and Bcat2p.Q300*/p.Q300*
mice (n = 15 cardiomyocytes from 4 mice). (E) Representative immunoblots of total mTOR, phosphorylated mTOR (P-mTOR) at ser2448 and GAPDH
from heart lysates (apex) from Bcat2þ/þ and Bcat2p.Q300*/p.Q300* mice. (F) Average total mTOR and phosphorylated P-mTOR expression normalized to
GAPDH, and ratio of normalized P-mTOR on normalized total mTOR from Bcat2þ/þ (n = 7) and Bcat2p.Q300*/p.Q300* (n = 6) mouse heart
lysates.*P < 0.05; #P <_ 0.001 (with Student’s t-test or Mann–Whitney Rank sum test).



























was also significantly increased in Bcat2p.Q300*/p.Q300* hearts
(Supplementary material online, Figure S9 and Table S2). The functional
contribution of mTOR pathway activation to the observed pro-
arrhythmic effects of BCAAs was subsequently demonstrated in hPSC-
CMs. Incubation with the mTOR inhibitor rapamycin (500 nmol/L) pre-
vented the APD90 prolongation and EAD/DAD incidence (Figure 6A–D),
as well as the calcium dysregulation and after-transient occurrence
(Figure 7A–D) induced by increased BCAA levels (Supplementary mate-
rial online, Table S6), whereas it had no electrophysiological effects in the
absence of high BCAA levels (Supplementary material online, Table S7).
These observations demonstrate the functional involvement of mTOR
pathway activation in the pro-arrhythmic effects of elevated BCAA
levels.
3.7 Plasma BCAA levels correlate with
ECG parameters in the general population
Finally, to confirm a modulatory role of BCAAs on cardiac electrical
function in humans, we investigated the relation between ECG measures
and BCAA plasma levels in 2304 participants (mean age
51.5 ± 10.6 years; 52.6% women) from the German community-based
KORA F4 Study.14 Average ECG parameters were: heart rate 63.8± 9.7
b.p.m., PR interval 165.9 ± 23.2 ms, QRS duration 93.4± 11.8 ms, and
QTc interval 422.3± 20.4 ms. The mean concentration of valine was
275.4± 60.2mmol/L and of xleucine was 213.2 ± 45.2mmol/L. Both valine
and xLeucine followed a normal distribution, and showed a linear rela-
tion with ECG parameters (Supplementary material online, Figure S11).
Figure 6 Increased levels of BCAAs recapitulate the pro-arrhythmic phenotype in hPSC derived cardiomyocytes (hPSC-CMs) which is reversible
upon mTOR inhibition. (A) Typical example of APs elicited at a stimulation frequency of 1 Hz from hPSC-CMs incubated with control medium or with in-
creased levels of BCAAs in the presence or absence of the mTOR inhibitor rapamycin (500 nmol/L). (B) Average values for APA (AP amplitude), RMP
(resting membrane potential), Vmax (upstroke velocity), and APD (action potential duration) at 20%, 50%, and 90% repolarization (APD20, APD50, and
APD90) of hPSC-CMs incubated with the control medium (n = 25 hPSC-CMs from 5 dissociations), with increased levels of BCAAs (n = 25 hPSC-CMs
from 5 dissociations), and with increased BCAA levels and rapamycin (n = 24 hPSC-CMs from 5 dissociations). (C) Typical examples of EADs (1) and
DADs (2) recorded after a fast-pacing stimulation protocol (20 pulses at 3 Hz followed by an 8 s pause and 1 pulse followed by a 1 s pause). (D) Average
count per trace for DADs and EADs observed in hPSC-CMs incubated with the control medium (n = 23 hPSC-CMs from 5 dissociations), with increased
levels of BCAAs (n = 24 hPSC-CMs from 5 dissociations), and with increased BCAA levels and rapamycin (n = 19 hPSC-CMs from 5 dissociations).
Average numbers were calculated using five consecutive traces. *P < 0.05, one-way ANOVA (with Student–Newman–Keuls Method post hoc test) or
one-way ANOVA on ranks (with Dunn’s method post hoc test).





















Regression results between ECG measures and BCAAs are presented in
Table 1. We observed significant sex-adjusted associations between fast-
ing valine plasma levels and the ECG parameters PR interval, QRS dura-
tion, and QTc interval. This association was consistent across men and
women for the PR interval, and maintained effect directionality for QRS
duration and QTc interval. Overall, the effect size was strongest for PR
interval (beta: 0.0335± 0.0085 ms/mmol/L; P < 0.001), for which we also
identified a significant association with xLeucine (i.e. the combination of
Leucine and Isoleucine; beta: 0.0270 ± 0.0125 ms/mmol/L; P < 0.05).
Together with the observations in Bcat2p.Q300*/p.Q300* mice, these find-
ings indicate that higher plasma BCAA levels are associated with altered
cardiac conduction and repolarization.
4. Discussion
Through a phenotype-driven random mutagenesis screen11 we here
identified a mutant mouse line presenting with a striking, highly penetrant
Figure 7 Abnormal intracellular calcium regulation in human PSC derived cardiomyocytes (hPSC-CMs) with elevated BCAAs is reversible upon
mTOR inhibition. (A) Typical examples of intracellular calcium transient recordings in hPSC-CMs performed at a pacing frequency of 1 Hz. (B) Average
values for diastolic Ca2þ, peak transient and transient amplitude with control medium (n = 22 hPSC-CMs from 3 dissociations), increased BCAA levels
(n = 24 hPSC-CMs from 3 dissociations), and with increased BCAA levels and rapamycin at 500 nmol.L-1 (n = 22 hPSC-CMs from 3 dissociations). (C)
Typical example of calcium after-transients in hPSC-CMs incubated with a control medium or with increased levels of BCAAs following a fast-pacing pro-
tocol using field stimulation and (D) quantification of non-triggered action potential (AP) Ca2þ transient, triggered AP Ca2þ transient and total Ca2þ tran-
sient events in hPSC-CMs incubated with the control medium (n = 17 hPSC-CMs from 2 dissociations), with increased levels of BCAAs (n = 16 hPSC-
CMs from 2 dissociations), and with increased BCAA levels and rapamycin (n = 14 hPSC-CMs from 2 dissociations). *P < 0.05, one-way ANOVA on ranks
(with Dunn’s method post hoc test).







































































phenotype of sudden death without prior symptoms. The causative mu-
tation was determined to be a nonsense mutation in the Bcat2 gene
resulting in a defect in BCAA catabolism and the accumulation of high
levels of BCAAs in plasma and urine. Detailed electrophysiological stud-
ies unravelled a robust arrhythmogenic phenotype in affected mice, and
additional studies in hPSC-CMs confirmed a direct pro-arrhythmic effect
of elevated BCAAs levels. We therefore identified for the first time a
role for BCAA dysregulation in modulating cardiac electrophysiology
and risk for cardiac arrhythmias and sudden death.
BCAT2 is located in the mitochondria of most cells of the body, and is
responsible for catabolizing branched chain amino acids (BCAAs; leu-
cine, isoleucine, and valine), essential amino acids that must be obtained
from dietary sources. Following catabolism by either BCAT2 or BCAT1
(the cytosolic isoform) to their respective a-keto acids (BCKA), BCAAs
are further catabolized by the BCKDC.24 The final catabolic products of
BCAAs are consumed in mitochondria for respiration through the tri-
carboxylic acid cycle. Defects in BCAA catabolism have been associated
with the development of Maple Syrup Urine disease (MSUD), an autoso-
mal recessive metabolic disorder associated with brain damage caused
by mutations in genes of the branched chain BCKDC complex.24 Here,
the block in BCAA catabolism prevents the catabolism of BCKAs, the
catabolic product resulting from the action of the two BCAT enzymes,
cytosolic and mitochondrial. MSUD patients exhibit a failure to thrive
and neurological deterioration thought to be associated with the accu-
mulation of BCKAs.24 This was mirrored in a different, previously pub-
lished mouse line with an ENU-induced Bcat2, which resulted in the 50
splice site in Bcat2 and the deletion of exon 2 with an absence of mature
BCAT2 protein.28 These mutant mice displayed failure to thrive, reduced
body weight and early death; no details were provided on the early death
phenotype, and cardiac (electrophysiological) characterization was not
performed. Analysis of the plasma revealed increased levels of both
BCAAs (albeit it to a lower extent as compared to Bcat2p.Q300*/p.Q300*
mice) and BCKAs, with the latter prevented from entering the mito-
chondria and therefore accumulating. In contrast, our Bcat2p.Q300*/
p.Q300* mutation results in the production of a truncated protein, no dif-
ferences in body weight, an accumulation of BCAAs but not BCKAs, and
a sudden death phenotype. In particular, the absence of neuronal damage
is likely due to the fact that BCKAs in Bcat2p.Q300*/p.Q300* mice were not
elevated and hence glutamate signalling not disturbed. Mice with tar-
geted deletion of exon 4–6 of Bcat2 demonstrated lower body weight
and exercise intolerance, while their BCKA plasma levels remained nor-
mal.29 The lack of accumulation of BCKAs in our mice implies that the
BCKA transport mechanism is intact in Bcat2p.Q300*/p.Q300* mice but not
in the previously described Bcat2 deficient mice, as catabolism of BCKAs
occurs within the mitochondria.24 This suggests that the truncated
BCAT2Q300* protein has impaired transamination activity yet retained
BCKA transport activity30,31 either in the truncated protein or by main-
taining the interaction of BCAT2 with a separate transport protein. This
is supported by the observation that in our mice the concentration of va-
line is higher than that observed in the null mice. Hence, our novel
mouse model presenting specific BCAA accumulation in the absence of
BCKAs allows the investigation of the physiological effects of an excess
of BCAAs, and the dissection of the transamination and BCKA transport
activities of BCAT2. Additionally, all murine Bcat2 models described so
far were generated in C57BL/6J mice, a murine strain known to present
distinct mitochondrial calcium and reactive oxygen species (ROS) han-
dling properties demonstrated to be protective in heart failure models.32
In our present study, after the initial ENU mutagenesis step, mice were
backcrossed onto the C3H background strain which may explain the se-
vere phenotype severity observed in Bcat2p.Q300*/p.Q300* mice.
Our findings identify a profound effect of elevated BCAA levels on in-
tracellular calcium handling. Despite the substantial increase in diastolic
and systolic [Ca2þ]i in Bcat2
p.Q300*/p.Q300* cardiomyocytes, the Ca2þ gra-
dient across the SR membrane and the decay time of the Ca2þ transient
remained unaltered, arguing against underlying alterations in phosphory-
lation state. Taken together, we consider the altered diastolic [Ca2þ]i as
the main driver for the observed pro-arrhythmic calcium dysregulation
in Bcat2p.Q300*/p.Q300* cardiomyocytes. Elevated diastolic Ca2þ, which
has been shown to increase both the systolic Ca2þ as well as the SR
Ca2þ content,33 may be the consequence of various processes affecting
ionic gradients across cell membranes, including altered energetic me-
tabolism. Together with the increase in SR Ca2þ, elevated diastolic Ca2þ
leads to a higher open probability of the ryanodine channels and the like-
lihood of spontaneous Ca2þ release from the SR. Subsequent calcium
removal by the NCX may then lead to membrane (after)depolarization
and onset of arrhythmia. Of note, late sodium current density was not al-
tered and hence unlikely to have contributed to the AP prolongation,
EAD incidence, and Ca2þ dysregulation observed in in Bcat2p.Q300*/
p.Q300* cardiomyocytes. In line with the in vivo and ex vivo findings in the
Bcat2p.Q300*/p.Q300* mice, AV conduction (PR interval), and repolariza-
tion (QT interval) ECG traits were significantly correlated with BCAA
plasma concentrations in the KORA cohort. These results indicate a
modulatory effect of BCAAs on electrophysiological characteristics of
both the working myocardium and the cardiac conduction system,
............................................ ............................................ ............................................
..............................................................................................................................................................................................................................
Table 1 Association of ECG measures with branched-chain amino acids in the KORA F4 Study
Unstratified Men Women
ECG measure BCAA Beta (SE) P-value Beta (SE) P-value Beta (SE) P-value
Heart rate (b.p.m.) Valine (mmol/L) 0.0035 (0.0036) 0.34 0.0017 (0.0053) 0.75 0.0054 (0.0050) 0.28
Leucine (mmol/L) 0.0026 (0.0053) 0.61 0.0051 (0.0073) 0.49 -0.0004 (0.0077) 0.96
PR (ms) Valine (mmol/L) 0.0335 (0.0085) <0.001 0.0264 (0.0126) 0.036 0.0410 (0.0115) <0.001
Leucine (mmol/L) 0.0270 (0.0125) 0.031 0.0226 (0.0175) 0.20 0.0327 (0.0179) 0.07
QRS (ms) Valine (mmol/L) -0.0086 (0.0042) 0.040 -0.0134 (0.0062) 0.030 -0.0034 (0.0056 0.54
Leucine (mmol/L) -0.0069 (0.0061) 0.26 -0.0134 (0.0086) 0.12 0.0016 (0.0087) 0.86
QTc (ms) Valine (mmol/L) 0.0234 (0.0075) 0.002 0.0173 (0.0108) 0.11 0.0297 (0.0104) 0.004
Leucine (mmol/L) 0.0144 (0.0110) 0.19 0.0032 (0.0150) 0.83 0.0287 (0.0161) 0.08
Linear regression models excluded participants <_50 kg body weight, >_70 years of age, or with diabetes mellitus. Unstratified models adjusted for sex.
Beta, standardized regression coefficient; P, P-value; SE, standard error. Data were considered significant below a P-value of 0.05 (indicated in boldface).

































































































suggesting that ventricular arrhythmias as well as conduction defects
could be triggered by elevated BCAA levels. Conduction through the
central part of the AV-node is mainly calcium-driven, and we have re-
cently demonstrated that intracellular calcium dysregulation may signifi-
cantly contribute to AV-conduction.34 Hence, BCAA-induced calcium
dysregulation may affect AV-conduction through prolonged repolariza-
tion and/or reduced gap junctional conductance within the central AV-
node. Additionally, while myocardial fibrosis was not increased in
Bcat2p.Q300*/p.Q300* mice, minor structural remodelling within the AV-
nodal area may still have impacted on AV-conduction. Finally, the AV-
nodal region is highly innervated and a modulatory role of BCAAs on
neuronal function has been previously demonstrated in neurons,35 pro-
viding another potential mechanism by which AV-conduction may have
been affected. Interestingly, gender differences in electrophysiological
effects of BCAAs appear to be present in both humans (Table 1) and
mice (see Supplementary material online, Table S9), which may be due to
intrinsic BCAA concentration differences between men and women,36
and/or gender-related differences in ion channels, exchangers and cal-
cium handling.37,38
Importantly, the electrophysiological changes and pro-arrhythmic
events observed in hPSC-CMs incubated with elevated BCAA levels
confirm a direct pro-arrhythmic effect of BCAAs in cardiomyocytes. To
date, BCAT2 human mutations have been reported in only six individuals,
associated mainly with developmental delay and autistic features.39
Affected individuals displayed elevated plasma BCAA levels of up to
4 mmol/L (valine), with plasma BCKA levels remaining unchanged as in
Bcat2p.Q300*/p.Q300* mice. Interestingly, valine levels were generally more
elevated than leucine and isoleucine in BCAT2 mutation carriers,39,40 sim-
ilar to our findings in Bcat2p.Q300*/p.Q300* mice. Valine appears to play a
central role in BCAA-induced electrophysiological abnormalities, as evi-
denced by our findings in hPSC-CMs that increased levels of valine only
were sufficient to induce pro-arrhythmic effects. Moreover, we ob-
served the strongest correlation with ECG parameters for valine in the
KORA cohort. While MSUD patients also have elevated BCAA plasma
levels, arrhythmias have not been reported but cardiac electrophysiolog-
ical assessment is likely not routinely performed. Similarly, arrhythmias
have as yet not been reported in BCAT2 mutation carriers, but our
results suggest that an in-depth cardiac electrophysiological investigation
and follow-up could be beneficial for these patients as well as individuals
suffering MSUD.
Acute BCAA administration has been shown to reduce infarct size
and exert cardioprotective effects during myocardial ischemia-reperfu-
sion.41 In contrast, chronic BCAA administration was found to exacer-
bate cardiac dysfunction and remodelling following myocardial
infarction, and furthermore increased myocardial vulnerability to ischae-
mia–reperfusion injury by enhancing glycolysis and fatty acid oxida-
tion.42,43 Taken together, these findings and our current observations
suggest time-dependent effects triggered by BCAAs, with acute adminis-
tration presenting potential benefits while a chronic exposure would be
deleterious for cardiac (electrical) function. Crucially, we here demon-
strate pro-arrhythmic actions of chronically elevated BCAA levels
through direct effects on the cardiomyocyte level outside of the cardiac
ischaemia–reperfusion context.
The striking rapamycin-mediated reversal of pro-arrhythmic events in
hPSC-CMs as well as the absence of effect of rapamycin in non-BCAA
treated cells suggest a central role of mTOR on the electrophysiological
dysfunctions triggered by elevated BCAAs. A number of studies have im-
plicated increased ROS production secondary to mTOR pathway activa-
tion in the detrimental effects of BCAAs supporting our current
observations.35,44 ROS-driven oxidative stress is known to induce pro-
arrhythmic calcium dysregulation in cardiomyocytes as observed in our
Bcat2p.Q300*/p.Q300* mice.45 Interestingly, two recent studies have shown
that low-BCAA diets can improve life-span through a decreased activa-
tion of the mTOR pathway, suggesting that dietary intervention could
represent a preventive option in patients with elevated BCAA plasma
levels.46,47 The activation of the mTOR molecular pathway has also been
linked to cardiac hypertrophy and structural remodelling.48,49 While
Bcat2p.Q300*/p.Q300* mice showed absence of fibrosis and normal cardiac
dimensions, they did display increased ventricular transcript levels of Anf,
indicating that pro-hypertrophic remodelling, likely secondary to mTOR
pathway activation, preceded sudden death. We hypothesize that BCAA
levels in affected mice rose drastically within a short period of time fol-
lowing weaning, causing severe electrophysiological changes and sudden
death before more overt cardiac remodelling such as fibrosis could oc-
cur. BCAAs have also been shown to regulate AMP-activated protein ki-
nase (AMPK),25 which functions as a metabolic sensor in
cardiomyocytes. Interestingly, AMPK can directly modulate sarcolemmal
ion channels and transporters, providing an additional pathway through
which BCAAs can impact on cardiomyocyte electrophysiology.50,51
Crucially, the pro-arrhythmic potential of the clinically observed in-
creased BCAA levels may be enhanced by conditions that further com-
promise either BCAA catabolism or cardiac conduction and
repolarization, such as for instance metabolic disturbances, certain QT-
prolonging drugs, and structural alterations (cardiac hypertrophy, fibro-
sis). BCAA dysregulation is furthermore an increasingly recognized fea-
ture of diabetes mellitus, obesity, and heart failure, acquired disorders
associated with an increased risk for arrhythmias and SCD.4–6,15–17,52
Our current observations suggest that enhanced BCAA plasma levels as
observed in metabolic syndromes may underlie, at least in part, the in-
creased susceptibility to cardiac arrhythmias and SCD observed in these
patients, constituting a potential target for the prevention and treatment
of cardiac arrhythmias in this setting.
4.1 Limitations
The ENU mutagenesis approach is a powerful tool for identifying poten-
tial novel genes and pathways but is inherently limited by the fact that a
potential role for additional ENU-induced mutations besides
Bcat2p.Q300*/p.Q300* cannot be completely ruled out. Nevertheless, the
sudden death phenotype remained after backcrossing the mice onto an-
other genetic background, strengthening the involvement of the
Bcat2p.Q300*/p.Q300* mutation. Importantly, the identification of the Bcat2
mutation led to the discovery of elevated BCAA plasma levels in affected
mice and the subsequent establishment of their pro-arrhythmic effects in
an independent system (hPSC-CMs). While we were not able to estab-
lish whether Bcat2p.Q300*/p.Q300* mice died from cardiac arrhythmia
(given the young age at which sudden death occurred), the robust
arrhythmogenic electrophysiological alterations in both Bcat2p.Q300*/
p.Q300* mouse cardiomyocytes and hPSC-CMs incubated with elevated
levels of BCAAs confirmed a pro-arrhythmic effect of the latter.
Bcat2p.Q300*/p.Q300* mice presented with severely elevated BCAA levels
whereas BCAA plasma levels in the KORA cohort were markedly lower.
However, KORA participants provided a fasting blood sample, were not
supplementing BCAAs for nutritional purposes, and were considered
healthy (i.e. not metabolically compromised). Hence, even under normal
circumstances in the general population, BCAAs are associated with car-
diac conduction and repolarization. It will be an interesting future investi-
gation to study if strongly increased BCAA levels in humans, as it is the
case with nutritional supplementation or in the setting of metabolic




























































































disorders such as obesity or diabetes, result in even more pronounced
ECG changes and/or arrhythmias. Milder elevations of BCAA levels fol-
lowing a longer exposure may also trigger cardiac structural remodelling
through mTOR pathway activation. Both electrophysiological and struc-
tural consequences may be of significance in patients presenting an al-
tered BCAA metabolism as well as in athletes supplementing their diet
with BCAAs.
5. Conclusion
Using an unbiased approach, we have identified BCAA metabolism as a
novel modulator of cardiac electrical function and a mediator of cardiac
arrhythmias and sudden death. This new mechanism linking BCAAs to
pro-arrhythmia may not only be relevant for inherited BCAT2 defi-
ciency, but also for acquired metabolic disorders such as diabetes, obe-
sity, and heart failure in which BCAA metabolism is impaired. Since
cellular BCAA metabolism is reflected by BCAA plasma levels, the latter
may serve as a circulating prognostic biomarker of arrhythmia and SCD
risk. Moreover, such metabolic mechanisms are modifiable through e.g.
dietary interventions, providing novel preventive and therapeutic targets
that overcome the drawbacks of conventional anti-arrhythmic
approaches targeting ion channels or transporters. Additionally, we here
provide the first proof of concept that pharmacological inhibition of the
mTOR pathway can abolish the pro-arrhythmic events provoked by ele-
vated BCAAs. Overall, our findings pave the way for novel research into
therapeutic strategies aimed at preventing electrical dysfunction and
arrhythmogenesis in patients suffering from diabetes, obesity, and heart
failure.
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17. Ruiz-Canela M, Guasch-Ferré M, Toledo E, Clish CB, Razquin C, Liang L, Wang DD,
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Translational perspectives
Development of efficient anti-arrhythmic strategies is hampered by incomplete knowledge of disease mechanisms. Using an unbiased approach, we
here identified for the first time a pro-arrhythmic effect of increased levels of branched chain amino acids (BCAAs). This is of particular relevance
for conditions associated with BCAA dysregulation and increased arrhythmia risk, including heart failure, obesity and diabetes, as well as for athletes
supplementing their diet with BCAAs. Such metabolic dysregulation is potentially modifiable through dietary interventions, paving the way for novel
preventive strategies. Our findings furthermore, identify mTOR inhibition as a potential anti-arrhythmic strategy in patients with metabolic
syndrome.
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